Get to know our clinical trials
Clinical trial to evaluate the safety and efficacy of new interventions and treatment combinations in participants with colorectal cancer
THE PURPOSE OF THIS STUDY IS TO LEARN MORE ABOUT THE EFFECTIVENESS AND SAFETY OF THE STUDY DRUG, VOLRUSTOMIG (ALSO KNOWN AS MEDI5752), WHEN GIVEN IN COMBINATION WITH A STANDARD TREATMENT FOR COLORECTAL CANCER.
Technical Summary
- A PHASE 2, OPEN-LABEL, MULTICENTER STUDY USING A MASTER PROTOCOL TO EVALUATE THE SAFETY AND EFFICACY OF NEW INTERVENTIONS AND TREATMENT COMBINATIONS IN PARTICIPANTS WITH COLORECTAL CANCER (CANTOR)
- Code EudraCT: 2024-518469-84
- Protocol number: D798VC00001
- Promoter: Astra Zeneca AB
- Molecule/Drug: Volrustomig (MEDI5752)
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.